PERFUSE study – poster ACR Annual Meeting November 2019

Mis à jour : 25 nov. 2019

Biosimilars are biological medicines that are highly similar to another already approved biological medicine. They have to be approved according to the same high standards of pharmaceutical quality, safety and efficacy as all biological medicines. Biogen are one of Sanoïa’s prestigious clients and are pioneers in the commercialization of biosimilars.

An interim analysis that highlights recent findings of the ongoing PERFUSE study on the successful transition of patients with chronic inflammatory rheumatism from infliximab (IFX) to biosimilar SB2, will be presented at the American College of Rheumatology Annual Meeting 2019, November 10, in Atlanta.

Have a look at the poster!


e-Health Services SAS


  • LinkedIn Social Icône


(French Clinical Research Association)

Sanoïa is an agile Contract Research Organization for tailor-made Real-Life studies.